Prediction of Adverse Perinatal Outcome for Preeclampsia in Sichuan Province of China

Preeclampsia Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01804751
• Other study ID #: hx2ck2
• Status: Not yet recruiting
• Phase: N/A
• First received: March 1, 2013
• Last updated: August 24, 2015
• Start date: January 2016

Study information

• Verified date: June 2013
• Source: West China Second University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: China:science & technology department of sichuan province
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to build a model for the prediction of adverse perinatal outcome for preeclampsia in china

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 0
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• admitted with preeclampsia or had developed preeclampsia after admission

Exclusion Criteria:

• admitted in spontaneous labour or had achieved any component of the maternal outcome before either fulfilling eligibility criteria or collection of predictor data

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Pre-Eclampsia
• Preeclampsia

Locations

Country	Name	City	State
n/a

Sponsors (10)

Lead Sponsor	Collaborator
West China Second University Hospital	Chengdu Women's and Children's Central Hospital, Luzhou Medical College, Nanchong Central Hospital, pengzhou shi fuyou baojianyuan, people's hospital of Guang'an, Sichuan Academy of Medical Sciences, Sichuan Provincial Maternal and Child Health Care Hospital, Suining Central Hospital, The first people's hospital of Neijiang

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	maternal mortality		within 48h of eligibility
Secondary	serious central nervous system morbidity		within 48h of eligibility
Secondary	serious cardiorespiratory morbidity		within 48h of eligibility
Secondary	serious hepatic morbidity.		within 48h of eligibility
Secondary	serious renal morbidity		within 48h of eligibility
Secondary	serious haematological morbidity		within 48h of eligibility